Evommune, Inc. (EVMN) Stock Price
EVMNStock
$5.17
Market Cap$187.63M
P/E—
PEG Ratio—
Div yield—
Beta0.56
EVMN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-90.49%
Price vs S&P 500 (4W)-43.97%
VGM Score47.30
EVMN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.67 | -$0.89 | -32.84%(-$0.22) | |
| Q4 2025 | -$0.84 | -$1.43 | -69.83%(-$0.59) | |
| Q3 2025 | -$11.36 | -$8.07 | +28.93%(+$3.29) |
EVMN Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.35
4.12
4.12
4.11
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
EVMNEvommune, Inc. | — | A | F | 11.7x | — | — | — | $5.17 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Evommune, Inc.
Evommune Inc is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, including chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's pipeline features two lead candidates, EVO756 and EVO301, currently in clinical development.